Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
Biotech start-up Bionomic from Oegstgeest (South Holland) won the Innovation Promise Award on Friday during the twentieth edition of the announcement of the KVK Innovation Top...
The Dutch Life Sciences Conference 2025 was held on 20 November 2025 at the CORPUS Congress Centre in Oegstgeest, bringing together biotech and medtech companies, academic...
The Equals campaign is an initiative promoting gender equality in technology, science, and innovation. Its goal is to shine a spotlight on talented women, raise awareness about...